Evidence map›Paper›PMID 36604598›Full record

ArticleCell research2023

Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation.

Gang Du, Linlin Zhao, Yumei Zheng, Anissa Belfetmi, Tiantian Cai, Boying Xu, Karen Heyninck, Kim Van Den Heede, Marie-Ange Buyse, Pietro Fontana and 4 more

Open access · greenAbstract read
In one paragraph

Article in Cell research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. CD95/Fas stoichiometry in future precision medicine.Cell death and differentiation · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Gang Du *Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0805-4778
Linlin Zhao *Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Yumei ZhengDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Anissa BelfetmiDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Tiantian CaiDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Boying XuTongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Karen HeyninckSanofi, Technologiepark 21, Zwijnaarde, Belgium.
Kim Van Den HeedeSanofi, Technologiepark 21, Zwijnaarde, Belgium.
Marie-Ange BuyseSanofi, Technologiepark 21, Zwijnaarde, Belgium.
Pietro FontanaDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Michael BowmanCheckpoint Immunology, Immunology & Inflammation, Sanofi, Cambridge, MA, USA.
Lih-Ling LinCheckpoint Immunology, Immunology & Inflammation, Sanofi, Cambridge, MA, USA.
Hao WuDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. wu@crystal.harvard.edu.ORCID 0000-0002-7281-8579
James Jeiwen ChouDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. james_chou@hms.harvard.edu.ORCID 0000-0002-4442-0344
Harvard University · USBoston Children's Hospital · USSanofi (Belgium) · BESanofi (United States) · USTongji University · CN

Funding

CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORSR01AI150709 · NIAID · HARVARD MEDICAL SCHOOL · PI WAGNER, GERHARD, WU, HAO · 2020 to 2024
$4.0M
TR&D 4 -- Advanced Magic Angle Spinning NMR methodsP41GM132079 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GRIFFIN, ROBERT GUY · 2019 to 2021
$3.6M
New RF Electronics Console and Probes for 900 Mhz NMR SpectrometerS10OD023513 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GRIFFIN, ROBERT GUY · 2018 to 2018
$1.0M
Structural and Functional Roles of the Membrane-Related Components of Single-Pass Membrane ProteinsR35GM140887 · NIGMS · HARVARD MEDICAL SCHOOL · PI CHOU, JAMES JEIWEN · 2021 to 2022
$883k
NIAID NIH HHS R01 AI150709NIGMS NIH HHS P41 GM132079NIGMS NIH HHS R35 GM140887NIH HHS S10 OD023513
6 · The paper itself

Abstract

Members of the tumor necrosis factor receptor superfamily (TNFRSF) are important therapeutic targets that can be activated to induce death of cancer cells or stimulate proliferation of immune cells. Although it has long been implicated that these receptors assemble preligand associated states that are required for dominant interference in human disease, such states have so far eluded structural characterization. Here, we find that the ectodomain of death receptor 5 (DR5-ECD), a representative member of TNFRSF, can specifically self-associate when anchored to lipid bilayer, and we report this self-association structure determined by nuclear magnetic resonance (NMR). Unexpectedly, two non-overlapping interaction interfaces are identified that could propagate to higher-order clusters. Structure-guided mutagenesis indicates that the observed preligand association structure is represented on DR5-expressing cells. The DR5 preligand association serves an autoinhibitory role as single-domain antibodies (sdAbs) that partially dissociate the preligand cluster can sensitize the receptor to its ligand TRAIL and even induce substantial receptor signaling in the absence of TRAIL. Unlike most agonistic antibodies that require multivalent binding to aggregate receptors for activation, these agonistic sdAbs are monovalent and act specifically on an oligomeric, autoinhibitory configuration of the receptor. Our data indicate that receptors such as DR5 can form structurally defined preclusters incompatible with signaling and that true agonists should disrupt the preligand cluster while converting it to signaling-productive cluster. This mechanism enhances our understanding of a long-standing question in TNFRSF signaling and suggests a new opportunity for developing agonistic molecules by targeting receptor preligand clustering.

Indexed as

ApoptosisReceptors, TNF-Related Apoptosis-Inducing LigandCarrier ProteinsCell Line, TumorHumansSignal TransductionTNF-Related Apoptosis-Inducing LigandCarrier ProteinsReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing Ligand

Identifiers

PMID36604598
PMCPMC9892523
OpenAlexW4313555688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.